Telix Pharmaceuticals Limited has announced the acquisition of Advanced Nuclear Medicine Ingredients (ANMI) SA for €5.15m in cash and shares. The acquisition of ANMI expands the market opportunity for Telix’s investment in prostate cancer imaging and builds on the existing commercialization collaboration for the illumet prostate imaging (68Ga-PSMA) kit for the US market. Combining the resources, clinical data and human capital of both companies is expected to accelerate the process of prep...